# US 2015/0176065 A1 · Detection of pna clamping

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0176065 A1
- Document ID: US20150176065A1
- Status: Published application
- Kind: A1
- Application number: 14/472,240
- Filed: 2014-08-28
- Published: 2015-06-25
- Earliest claimed: 2013-06-28
- Assignees: Diacarta Ltd
- Inventors: Michael J. Powell; Aiguo Zhang
- Web page: https://patentgrep.com/patent/US20150176065A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6858: Allele-specific amplification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention provides methods and systems for detecting sequence variants in a sample nucleic acid. Methods include PNA clamping/PCR using primers with binding moieties followed by capture and detection of amplicons on a solid support. Systems include PCR reagents with primers having binding moieties, a PNA clamping probe, a solid support capable of capturing the PCR amplicons incorporating the binding moieties, and a detector device.

## Claims

### Claim 1

A method of detecting a variant in a target nucleic acid of interest, the method comprising:
providing a first pair of PCR primer probes which allow formation of a PCR process product comprising a sequence covering a first region of interest in the target nucleic acid, wherein at least one of the primer probes comprises a binding moiety;
providing a first PNA clamping probe fully complementary to a clamping target sequence in the nucleic acid target region of interest;
admixing the primer probes and clamping probe with a putative target nucleic acid sample;
performing a PCR amplification process in a reaction solution under hybridization conditions wherein the clamping probe hybridizes to a perfect complement clamping target sequence, but does not hybridize where there are one or more sequence variants in the clamping target sequence, thereby producing PCR amplicons comprising one or more primer probes only if the clamping target sequence includes one or more a sequence variants;
providing one or more capture moieties on a solid support, which capture moieties are adapted to bind the binding moiety;
contacting the solid support with the PCR reaction solution, thereby capturing PCR amplicons present in the solution; and,
interrogating the solid support to determine the presence or absence of bound amplicons on the solid support;
whereby the presence of a variant in the target sequence of interest is confirmed by detection of amplicons on the solid support.

### Claim 2 (depends on 1)

The method of claim 1, wherein the binding moiety or capture moiety is selected from the group consisting of: biotin, avidin, streptavidin, a hapten, an antibody, fluorescein, digoxigenin, a ligand, a receptor, a polynucleotide comprising a sequence complementary to a capture probe, and a polynucleotide comprising a sequence complementary to a bDNA detection probe.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nucleic acid target region of interest consists of a sequence selected from the group consisting of: an oncogene, a proto-oncogene, a tumor suppressor, a growth factor receptor, a tumor associated signal transduction protein kinase sequence, a K-Ras sequence, a B-Raf sequence, an EGFR sequence, a p53 sequence, a PI3KCA sequence, an IDH1 sequence, a JAK2 sequence, a PTEN sequence, an INK sequence, a pRb sequence, an ARF sequence, a mTOR sequence, an ALK sequence, and an Akt sequence, or a natural mutant thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the clamping target sequence in the nucleic acid target region comprises a sequence ranging from 12 bases to 25 bases.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sequence variant comprises a single base pair mismatch between the PNA probe and the target.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample is a cell lysate not extracted to separate nucleic acids from other lysate constituents before said admixture.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample comprises nucleic acids extracted from cell, nucleic acids extracted from tissue, purified nucleic acids, or synthetic nucleic acids.

### Claim 8 (depends on 1)

The method of claim 1, wherein solid support is selected from the group consisting of: beads, microparticles, a multiwell plate, a semiconductor, and a microplate.

### Claim 9 (depends on 1)

The method of claim 1, wherein the presence of the amplicons is detected using a bDNA assay.

### Claim 10 (depends on 1)

The method of claim 1, further comprising providing a second pair of PCR primer probes which allow formation of a PCR process product comprising a sequence covering a second region of interest in the target nucleic acid; and
providing a second PNA clamping probe fully complementary to a second clamping target sequence;
whereby both the first and second clamping target sequences can be evaluated for the presence of variants in the same sample.

### Claim 11

A system for detecting a variant in a target nucleic acid of interest, the system comprising:
a) PCR amplification process reaction solution comprising:
a pair of PCR primer probes which allow formation of a PCR process product comprising a sequence covering a region of interest in the target nucleic acid, wherein at least one of the primer probes comprises a binding moiety; and, a PNA clamping probe fully complementary to a clamping target sequence in the nucleic acid target region of interest;
b) a solid support comprising a surface with one or more capture moieties adapted to bind the binding moiety; and,
c) a detector adapted to detect one or more of the pair of primer probes on the solid support.

### Claim 12 (depends on 11)

The system of claim 11, wherein one or more of the primer probes comprise a binding target with an affinity for a label system.

### Claim 13 (depends on 11)

The system of claim 11, wherein the clamping probe is adapted to have a melting temperature less than the primer probe melting temperatures when the clamping target has a sequence variant.

### Claim 14 (depends on 11)

The system of claim 11, wherein the solid support is selected from the group consisting of: beads, microparticles, a semiconductor, and a microplate.

### Claim 15 (depends on 11)

The system of claim 11, wherein the one or more capture moieties are biotin groups, bDNA capture probes, or capture extenders.

### Claim 16 (depends on 11)

The system of claim 11, wherein a first of the primer pair comprises a biotin, and a second of the primer pair comprises a fluorescein or a digoxigenin.

### Claim 17 (depends on 11)

The system of claim 11, further comprising a bDNA detection system comprising, label extenders, amplification multimers or label probes.

### Claim 18 (depends on 11)

The system of claim 11, wherein, further comprising a second pair of PCR primer probes different from the first pair, and a second PNA clamping probe fully complementary to a second clamping target sequence.
